Debate of the Decade: RCTs in the Era of Precision Oncology
How do you design clinical trials in the era of precision oncology? Are prospective randomized controlled trials necessary anymore? Drs. Ray Kurzrock, Vivek Subbiah, and Christopher Booth join Dr. Chadi Nabhan to answer these important questions.
Oral Paclitaxel Non-Inferior to IV Paclitaxel in HER2-Negative mBC
DESTINY-Breast06: T-DXd Outperforms Chemo in HER2-Low/Ultralow HR+ mBC Across Mutations
INAVO120: Inavolisib Delays Chemotherapy and Boosts OS in HR+/HER2– aBC